SKIN The Journal of Cutaneous Medicine

Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities

Amy Paller, Weily Soong, Mark Boguniewicz, Bob Geng, Jacob Thyssen, Aldana Rosso, Louise Steffensen, Shannon Schneider, Andreas Wollenberg

Page s322

PDF

Real-World Tralokinumab Use in Dupilumab-Experienced Patients: A Retrospective Multi-Center Case Series

Edward Herman, Jessica Burgy, Mona Shahriari

Page s321

PDF

Efficacy and Safety of Tralokinumab in US Adults with Moderate-to-Severe Atopic Dermatitis: A Post-hoc Analysis of ECZTRA3

Boni Elewski, Matthew Zirwas, Azra Kurbasic, Shannon Schneider, Ami Claxton, Jonathan Silverberg

Page 686-695

PDF

Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial

Amy Paller, Michael Cork, Chih-ho Hong, Weilly Soong, Shannon Schneider, Hannah Lo, Line Rosendahl Meldgaard Pedersen, Emilia Vacko, Andreas Wollenberg

Page s323

PDF

Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada

Jashin Wu, Sanjeev Balu, Nikolaj Birk Larsen, Ryan Pulleyblank, Liv Strømkjær, Aron Quah, Marni Wiseman

Page s317

PDF

Matching-Adjusted Indirect Comparison of the Efficacy of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis Beyond Week 16

Tiago Torres, Anne Sohrt Petersen, Aldana Mariela Rosso, Christian Moreira Taveira, José Manuel Carrascosa

Page s319

PDF

Neutralizing Interleukin-13 with Tralokinumab Reduces Abundance of S. aureus in Adolescents with Atopic Dermatitis

Lisa Beck, Stephan Weidinger, Marie Tauber, Hidehisa Saeki, Alan Irvine, Lawrence Eichenfield, Thomas Werfel, Petra Arlert, Azra Kurbasic, Mads Røpke, Amy Paller

Page s324

PDF

Tralokinumab Real-World Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis Adult Patients in the United States: 6-Month Interim Analysis

Peter Lio, Yestle Kim, Sanjeev Balu, Halley Costantino, Dawn Bates, Cassandra Rene, Amanda Lopez, Jennifer Soung

Page s318

PDF

Real-World Evidence Demonstrating Tralokinumab Onset of Action and Efficacy in Two Skin of Color Patients with Moderate-to-Severe Atopic Dermatitis

Daniel Tinker, Duane Dilworth

Page s325

PDF

Stability of Long-Term Therapeutic Responses to Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis

Andrew Blauvelt, Chih-ho Hong, Ketty Peris, Norito Katoh, Marie Tauber, Mahreen Ameen, Melinda Gooderham, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum, Kristian Reich

Page s412

PDF

Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control

Andrew Blauvelt, Richard G. Langley, Ketty Peris, Juan Francisco Silvestre, Norito Katoh, Marie Tauber, Andreas Pinter, Mahreen Ameen, Melinda Gooderham, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum, Kristian Reich

Page s376

PDF

Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks

Andreas Wollenberg, Michael Cork, Chih-Ho Hong, Azra Kurbasic, Emilia Vacko, Amy Paller

Page s377

PDF

Successful Tralokinumab Treatment for Hand and Foot Atopic Dermatitis in a Patient with Skin of Color: A Case Report

Porcia Love, Chloe J. Walker, MD, MHS

Page 1752-1756

PDF

Improvement of the Head and Neck Regions with Continuous Tralokinumab treatment for Up to 4 years in Adults with Moderate-to-Severe Atopic Dermatitis

Raj Chovatiya, Andreas Wollenberg, Simone Ribero, Hidehisa Saeki, Christian Øland, Louise Steffensen, Ann-Marie Tindberg, Jacob Thyssen, Andrew Blauvelt

Page s316

PDF

Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

Kristian Reich, Richard G. Langley, Juan Francisco Silvestre, Delphine Staumont-Salle, Antonio Costanzo, Andrew Pink, Amy Paller, Norito Katoh, Andreas Wollenberg, Richard B. Warren, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum, Eric Simpson

Page s375

PDF

Atopic dermatitis disease biomarkers strongly correlate with IL-13 levels, are regulated by IL-13, and are modulated by tralokinumab in vitro

Stephan Weidinger, Maxim A.X. Tollenaere, Katharina Drerup, Thomas Litman, Hanne Norsgaard

Page S42

Poster PDF

A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Andreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, Jonathan I Silverberg, Claire Birrell, Christopher Kell, Koustubh Ranade, Michelle Dawson, Rene van der Merwe

Page S29

Poster PDF

Real World Baseline Characteristics and Early Patient Reported Outcomes in Adult Patients with Moderate to Severe Atopic Dermatitis Treated with Tralokinumab

Peter Lio, Yestle Kim, Sanjeev Balu, Adriana Guana, Dawn Bates, deMauri Mackie, Halley Costantino, Amanda Lopez, Jennifer Soung

Page s145

Poster PDF

Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis

Jonathan Silverberg, Thomas Bieber, Amy Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Peter Foley, Erin Johansson, Martin Dossenbach, Bülent Akmaz, Marta Casillas, Andrei Karlsson, Raj Chovatiya

Page s313

PDF

Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review

Raj Chovatiya, Aseel Bin Sawad, Janine Fournier, Donna Fountain, Caroline Shaw, Jasmine Toomey, Mariola Vazquez, Anna M. Tallman, Doral Fredericks

Page s381

PDF

The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Amy Paller, Jonathan Silverberg, H. Chih ho Hong, Michael Cork, Luis Puig, Petra Arlert, Azra Kurbasic, Lise Soldbro, Eric Simpson

Page s139

Poster PDF

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis

Page s74

Poster PDF

Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Marjolein de Bruin-Weller, Jacob P Thyssen, Lisa A Beck, Eric L Simpson, Shinichi Imafuku, Mark Boguniewicz, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Petra Arlert, Amy S Paller

Page s75

Poster PDF

Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2

Eric Simpson, Anderas Wollenberg, Weily Soong, Thomas Mark, Alexandra Kuznetsova, Louise Abildgaard Steffensen, Jonathan Silverberg

Page s61

Poster PDF

The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Amy S Paller, Jonathan I Silverberg, Chih-ho Hong, Michael Cork, Luis Puig, Petra Arlert, Azra Kurbasic, Lise Soldbro, Eric L Simpson

Page s77

Poster PDF

Search

Search Results